ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00792272
Recruitment Status : Completed
First Posted : November 17, 2008
Last Update Posted : July 22, 2013
Sponsor:
Collaborator:
Staten Island University Hospital
Information provided by (Responsible Party):
Suzanne El-Sayegh, Northwell Health

Brief Summary:
Dialysis patient could be more aspirin resistant than the general population based on data from chronic kidney disease patients

Condition or disease
Aspirin Resistance

Detailed Description:
We will try to describe the profile of aspirin resistant patient in hemodialysis patients

Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Prevalence of Aspirin Resistance in Hemodialysis Patients
Study Start Date : June 2008
Actual Primary Completion Date : November 2008
Actual Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis
Drug Information available for: Aspirin




Primary Outcome Measures :
  1. Aspirin Resistance in Hemodialysis patients [ Time Frame: 2 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
all hemodialysis patients on aspirin
Criteria

Inclusion Criteria:

  • all hemodialysis patients on aspirin

Exclusion Criteria:

  • low platelets <100.000
  • coagulopathy, bleeding disorders
  • patient on plavix

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00792272


Sponsors and Collaborators
Northwell Health
Staten Island University Hospital
Investigators
Principal Investigator: Suzanne El-Sayegh, MD SIUH

Responsible Party: Suzanne El-Sayegh, Assoc. Chair of Medicine, Northwell Health
ClinicalTrials.gov Identifier: NCT00792272     History of Changes
Other Study ID Numbers: 08-013
First Posted: November 17, 2008    Key Record Dates
Last Update Posted: July 22, 2013
Last Verified: July 2013

Keywords provided by Suzanne El-Sayegh, Northwell Health:
aspirin resistance
aspirin resistance in hemodialysis patients

Additional relevant MeSH terms:
Aspirin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics